AnaptysBio, Inc.
10421 Pacific Center Court
Suite 200
San Diego
California
92121
United States
Tel: 858-362-6295
Fax: 858-362-6296
Website: http://www.anaptysbio.com/
Email: info@anaptysbio.com
About AnaptysBio, Inc.
AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, our proprietary anti-interleukin-33 antibody, for the treatment of atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps.
In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.
Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.
Stock Exchange: NASDAQ
Stock Symbol: ANAB
110 articles with AnaptysBio, Inc.
-
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
5/4/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the first quarter ended March 31, 2022 and provided pipeline updates.
-
A roundup of last week's top clinical trial updates and news.
-
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
4/27/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced positive top-line data from a Phase 1 trial of ANB032, its investigational wholly owned anti-BTLA agonist antibody.
-
Despite being represented in clinical research, no solutions have been found to circumvent the effects of Alopecia areata. However, there may be hope.
-
In the interim, Daniel Faga will take the helm as president and CEO after Hamza Suria let go of his executive functions.
-
It was a busy week for clinical trial announcements. Here's a look.
-
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
3/21/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Daniel Faga as interim president and chief executive officer (CEO), effective immediately.
-
AnaptysBio announced that its drug candidate imsidolimab did not demonstrate efficacy in Phase II clinical trials in the treatment of moderate-to-severe acne.
-
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
3/14/2022
AnaptysBio, Inc. (Nasdaq: ANAB), today announced that top-line data from its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe acne, also known as the ACORN trial, did not demonstrate efficacy over placebo on primary or secondary endpoints.
-
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
3/7/2022
AnaptysBio, Inc. today reported operating results for the fourth quarter and year ended December 31, 2021 and provided pipeline updates.
-
AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio as part of the 40th Annual J.P. Morgan Healthcare Conference.
-
AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
11/29/2021
AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, announced the appointment of Mr. Daniel Faga to the company’s Board of Directors.
-
AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
11/16/2021
AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the 2021 Jefferies London Healthcare Conference.
-
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
11/15/2021
AnaptysBio, Inc. (Nasdaq: ANAB), today announced positive top-line data from a randomized placebo-controlled healthy volunteer single and multiple ascending dose Phase 1 trial of rosnilimab, its investigational wholly-owned anti-PD-1 agonist therapeutic antibody, previously known as ANB030.
-
AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates
11/4/2021
AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, reported operating results for the third quarter ended September 30, 2021 and provided pipeline updates.
-
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
10/2/2021
AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, announced that week 16 data from the GPP GALLOP Phase 2 trial of imsidolimab, its investigational anti-interleukin-36 receptor therapeutic antibody, was presented at the 2021 European Academy of Dermatology and Venereology Congress.
-
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
8/17/2021
AnaptysBio, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved a second indication for GSK’s JEMPERLI (dostarlimab-gxly)
-
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
8/9/2021
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the second quarter ended June 30, 2021 and provided pipeline updates.
-
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
5/27/2021
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Jefferies Virtual Healthcare Conference
-
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
5/4/2021
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the first quarter ended March 31, 2021 and provided pipeline updates.